Bioregnum channel feed – Endpoints News

Bioregnum channel feed

As the XBI suffers, Q1 shows a few comforting signs of underlying stability

3 weeks ago

Big ambitions at Merck and AstraZeneca — along with a few giant pitfalls — reshape top ranks of the R&D 15

Last month

Where the money is: The top 100 venture investors in biotech

2 months ago

A mixed year for deals and dollars left biotech execs hungry for a better 2025

3 months ago

The Endpoints 100: The biotech industry braces for Trump 2.0

5 months ago

Q3 biotech roundup: The 2024 turnaround sputters into a critical Q4 finale

6 months ago

You bet your life: After I was diagnosed with a rare cancer, I discovered how a small band of physician-scientists triggered a revolution

7 months ago

It’s time to nominate your favorite private biotech for this year’s Endpoints 11

10 months ago

After 14 years calling partnering shots at Genentech/Roche, James Sabry is headed back into the biotech fray

11 months ago

Trailblazers, iconoclasts and breakthrough artists are coming to the Endpoints biotech summit — please join us

12 months ago

Pascal Soriot’s been pushing for US-sized CEO pay for more than a decade. Now he’s finally getting it

Last year

Big comeback? The Q1 report on biotech is in, and there’s been some sputtering

Last year

The R&D 15: Top pharma players shell out record $153B for research, and M&A is a prime focus for all

Last year

The top 100 venture players in biopharma today. Who's in? What's out?

Last year

Lawmakers’ explosive charges turn a global spotlight on China’s WuXi, and it’s feeling the heat

Last year

We just had a string of successful biotech IPOs. Now what?

Last year

Biotech dealmaking shows some signs of a turnaround. And the industry is keeping its fingers crossed

Last year

As the biotech funding game changed, TCGX altered course — and now they’re back with $1B for round two

Last year

Headed to San Francisco? Here’s how you can customize your experience at #JPM24 with Endpoints News

Last year

The Endpoints 100 survey: Has biotech hit rock bottom?

Last year

Flagship Pioneering takes another big step across the globe, planting its biotech flag in Asia

Last year

Longtime cancer R&D chief Peter Lebowitz is taking his final bows at J&J oncology. Now what?

Last year

I'll be in London next week with the Endpoints crew and a great lineup of biotech experts and insiders. Join us

Last year

Q3 snapshot: The IPO market shows fresh signs of improvement, but the biotech crunch continues to bite

Last year

12 3 4 Next page Last page